SynthesisTransplant infectious disease : an official journal of the Transplantation Society2020
Antifungal prophylaxis in lung transplant recipients: A systematic review and meta-analysis.
Synthesis in Transplant infectious disease : an official journal of the Transplantation Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Effectiveness and safety of strategies to optimise antimicrobial use in solid organ transplant recipients. Systematic review and meta-analyses.EClinicalMedicine · 2025Article
- Bridging Echinocandin With Azole Antifungal Therapy on Prevention of Invasive Candidiasis Post-Lung Transplantation.Open forum infectious diseases · 2024Article
- ERS International Congress 2023: highlights from the Thoracic Surgery and Lung Transplantation Assembly.ERJ open research · 2024Article
- Invasive Aspergillosis among Lung Transplant Recipients during Time Periods with Universal and Targeted Antifungal Prophylaxis-A Nationwide Cohort Study.Journal of fungi (Basel, Switzerland) · 2023Article
- Adverse Events Associated with Universal versus Targeted Antifungal Prophylaxis among Lung Transplant Recipients-A Nationwide Cohort Study 2010-2019.Microorganisms · 2022Article
- Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Review
- Fungal infections in lung transplantation.Journal of thoracic disease · 2021Review
- The Impact of Antifungal Prophylaxis in Lung Transplant Recipients.Annals of the American Thoracic Society · 2021Article
- Strategies for the Prevention of Invasive Fungal Infections after Lung Transplant.Journal of fungi (Basel, Switzerland) · 2021Review
- Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis.Infection and drug resistance · 2021Review
- An Update on Invasive Fungal Infections in Solid Organ Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNo consensus exists regarding optimal strategy for antifungal prophylaxis following lung transplant.
objectiveTo review data regarding antifungal prophylaxis on the development of fungal infections. STUDY SELECTION/APPRAISAL: We searched MEDLINE, Embase, and Scopus for eligible articles through December 10, 2019. Observational or controlled trials published after January 1, 2001, that pertained to the prevention of fungal infections in adult lung recipients were reviewed independently by two reviewers for inclusion.
methodsOf 1702 articles screened, 24 were included. Data were pooled using random effects model to evaluate for the primary outcome of fungal infection. Studies were stratified by prophylactic strategy, medication, and duration (short term < 6 months and long term ≥ 6 months).
resultsWe found no difference in the odds of fungal infection with universal prophylaxis (49/101) compared to no prophylaxis (36/93) (OR 0.76, CI: 0.03-17.98; I
conclusionsWe have insufficient evidence to support or exclude a benefit of antifungal prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.